GSK Jun 2024 44.000 call
| Previous close | 1.1000 |
| Open | 1.1500 |
| Bid | 1.4500 |
| Ask | 1.5500 |
| Strike | 44.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.1000 - 1.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 24.86k |
Fool.co.uk2 top-quality businesses to consider buying from the FTSE 100 in June
It's been a brilliant start to the year for the FTSE 100. Here are two stocks this Fool thinks might be smart buys to think about actioning this month. The post 2 top-quality businesses to consider buying from the FTSE 100 in June appeared first on The Motley Fool UK.
Fool.co.ukThese FTSE 100 shares could rise 15% to 36% in the next year!
Is the market underestimating these top FTSE 100 stocks? Royston Wild explains why analysts expect these two blue-chip shares to rocket in value. The post These FTSE 100 shares could rise 15% to 36% in the next year! appeared first on The Motley Fool UK.
BenzingaZantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
A Chicago jury rejected an Illinois woman’s claim that the discontinued heartburn drug Zantac caused her colon cancer. This case is the first of thousands of similar lawsuits. The jury in Cook County, Illinois, found that Angela Valadez, an 89-year-old Illinois resident, did not prove her cancer was linked to her Zantac use. Related: GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims. Valadez alleged that her cancer resulted from taking over-the-
